Evidence of altered homocysteine metabolism in chronic renal failure

被引:44
作者
Henning, BF
Riezler, R
Tepel, M
Langer, K
Raidt, H
Graefe, U
Zidek, W
机构
[1] Ruhr Univ Bochum, Marienhosp Herne, Med Klin 1, D-44625 Herne, Germany
[2] Severi Med Gmbh, Munster, Germany
[3] KfH Dialysis Ctr, Munster, Germany
来源
NEPHRON | 1999年 / 83卷 / 04期
关键词
chronic renal failure; homocysteine metabolism; alterations; homocysteine levels;
D O I
10.1159/000045423
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The fasting serum concentrations of total homocysteine and metabolites of transsulfuration (cystathionine, cysteine, methylmalonic acid, 2-methylcitric acid) and remethylation (methionine) were determined by gas chromatography-mass spectrometry in 40 nondialyzed patients with chronic renal disease and in 50 patients with end-stage renal disease requiring chronic maintenance hemodialysis. The nondialyzed patients and 28 of the dialysis patients did not receive additional vitamin supplementations. Twenty-two of the dialysis patients received daily oral vitamin preparations containing 10 mg pyridoxine (vitamin B-6), 6 mu g cyanocobalamin (vitamin B-12), and 1 mg folic acid. In the nondialyzed patients, linear regression analysis showed positive correlations between serum concentrations of creatinine and total homocysteine (r = 0.68, p < 0.0001), cystathionine (r = 0.73, p < 0.0001), methylmalonic acid (r = 0.77, p < 0.0001), and 2-methylcitric acid (r = 0.81, p < 0.0001). Serum homocysteine was positively correlated with serum concentrations of cystathionine (r = 0.59, p < 0.0001), cysteine (r = 0.69, p = 0.004), methylmalonic acid (r = 0.64, p = 0.0001), and 2-methylcitric acid (r = 0.64, p < 0.0001). There was no significant correlation between serum concentrations of homocysteine and methionine (r = -0.14, p = 0.63). In the hemodialysis patients receiving oral vitamin supplementation, serum homocysteine and cystathionine concentrations were significantly lower than in hemodialysis patients not receiving vitamins (homocysteine 21.8 +/- 1.1 vs. 33.2 +/- 3.7 mu mol/l, p 0.0004; cystathionine 2,075.9 +/- 387.1 vs. 3,171.3 +/- 680.2 nmol/l, p = 0.02; mean +/- SEM). In summary, our results show increased intermediate products of the transsulfuration pathway, but no increase in remethylation of homocysteine in chronic renal disease, including end-stage renal disease requiring chronic maintenance dialysis. Copyright (C) 1999 S. Karger AG, Basel.
引用
收藏
页码:314 / 322
页数:9
相关论文
共 47 条
[11]  
CHAUVEAU P, 1993, KIDNEY INT S41, V43, P72
[12]   HYPERHOMOCYSTEINEMIA - AN INDEPENDENT RISK FACTOR FOR VASCULAR-DISEASE [J].
CLARKE, R ;
DALY, L ;
ROBINSON, K ;
NAUGHTEN, E ;
CAHALANE, S ;
FOWLER, B ;
GRAHAM, I .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (17) :1149-1155
[13]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41
[14]  
Cohen B D, 1977, Proc Clin Dial Transplant Forum, V7, P178
[15]   HOMOCYSTEINEMIA - DEPRESSED PLASMA SERINE LEVELS [J].
DUDMAN, NPB ;
TYRRELL, PA ;
WILCKEN, DEL .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1987, 36 (02) :198-201
[16]   HOMOCYSTINE UPTAKE IN ISOLATED RAT RENAL CORTICAL TUBULES [J].
FOREMAN, JW ;
WALD, H ;
BLUMBERG, G ;
PEPE, LM ;
SEGAL, S .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1982, 31 (06) :613-619
[17]   A CANDIDATE GENETIC RISK FACTOR FOR VASCULAR-DISEASE - A COMMON MUTATION IN METHYLENETETRAHYDROFOLATE REDUCTASE [J].
FROSST, P ;
BLOM, HJ ;
MILOS, R ;
GOYETTE, P ;
SHEPPARD, CA ;
MATTHEWS, RG ;
BOERS, GJH ;
DENHEIJER, M ;
KLUIJTMANS, LAJ ;
VANDENHEUVEL, LP ;
ROZEN, R .
NATURE GENETICS, 1995, 10 (01) :111-113
[18]  
GOYETTE P, 1995, AM J HUM GENET, V56, P1052
[19]   Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure [J].
Guttormsen, AB ;
Ueland, PM ;
Svarstad, E ;
Refsum, H .
KIDNEY INTERNATIONAL, 1997, 52 (02) :495-502
[20]   Renal uptake and excretion of homocysteine in rats with acute hyperhomocysteinemia [J].
House, JD ;
Brosnan, ME ;
Brosnan, JT .
KIDNEY INTERNATIONAL, 1998, 54 (05) :1601-1607